From Nasdaq, Inc.: 2025-06-01 23:24:00

HUTCHMED (China) Limited announced positive results from the SACHI Phase III study for the savolitinib and osimertinib combination in treating EGFR mutation-positive NSCLC with MET amplification. The combination shows promising efficacy, with a median PFS of 8.2 months compared to 4.5 months for chemotherapy in the ITT population. The ORR was 58% vs 34% for chemotherapy, and DCR was 89% vs 67%. Overall survival data is not yet mature. The safety profile was tolerable, with no new safety signals observed. This novel combination offers a convenient and well-tolerated treatment option for patients with this challenging disease.



Read more at Nasdaq, Inc.: HCM : Phase III Study Of Savolitinib Combo Shows Promising Results For EGFR-Mutated NSCLC Treatment